Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

Research Group
Breast and Gynecologic Cancer
University of Kansas Medical Center
Recruiting ID
For more information, see NCT04821141
Women at risk for development of breast cancer and experiencing vasomotor menopausal symptoms
(hot flashes) will be randomized to bazedoxifene (BZA) plus conjugated estrogens (CE) for 6
months versus a wait list control. Two risk factors for development of breast cancer will be
studied pre-study and after 6 months: fibroglandular volume (FGV) on mammogram as assessed by
Volpara software and proliferation by Ki-67 immunocytochemistry in benign breast tissue
acquired by random periareolar fine needle aspiration (RPFNA). Change in biomarkers will be
compared between groups.
Bazedoxifene and Conjugated Estrogens
Risk Reduction, Breast Cancer
Carol J Fabian, MD, Laura Esserman, MD, Lisa D Yee, MD, Victoria L Seewaldt, MD, Sema Khan, MD, Judy Garber, MD

See list of participating sites